FDA sets 'high bar' in interchangeability guidance

Fierce Pharma reported that the Food and Drug Administration (FDA) released draft guidelines which "outline requirements for biosimilar developers looking to prove that their versions are interchangeable with the original brands." The requirements for being designated interchangeable "appear to be more stringent than biosim makers would like. The current draft would require switching studies more complicated than many now in the works."